US 10751383
Doses and methods for administering telavancin
granted A61KA61K38/12A61K38/14
Quick answer
US patent 10751383 (Doses and methods for administering telavancin) held by Cumberland Pharmaceuticals Inc. expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cumberland Pharmaceuticals Inc.
- Grant date
- Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K38/12, A61K38/14, A61K47/40, A61K9/0019